Financials in USD. Standardized financial statements.
A compact view of how Renalytix Plc turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue? | $2.29M | $3.40M | $2.97M | $1.49M | $0 | $0 | $0 |
| Revenue Growth? | -32.7% | +14.6% | +99.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $2.13M | $2.68M | $2.10M | $804,000 | $0 | $30,484 | $0 |
| Gross Profit? | $156,000 | $720,000 | $874,000 | $687,000 | -$72,622 | -$30,484 | $0 |
| Gross Margin? | +6.8% | +21.2% | +29.4% | +46.1% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $29.76M | $42.94M | $54.06M | $33.30M | $11.08M | $6.54M | $410,163 |
| Operating Income? | -$29.61M | -$42.22M | -$53.18M | -$32.61M | -$11.08M | -$6.54M | -$410,000 |
| EBITDA? | -$28.52M | -$41.93M | -$52.69M | -$33.83M | -$10.24M | -$5.37M | $843,837 |
| Income Before Tax | -$33.45M | -$45.60M | -$45.25M | -$35.79M | -$9.84M | -$42.30M | -$410,000 |
| Income Tax Expense | $4,000 | $2,000 | $25,000 | -$4.78M | -$1.36M | -$959,000 | $0 |
| Net Income? | -$33.46M | -$45.61M | -$45.28M | -$34.73M | -$9.84M | -$42.30M | -$410,000 |
| EPS? | $-0.31 | $-0.55 | $-0.62 | $-0.43 | $-0.17 | $-0.15 | $-0.01 |
| Diluted EPS? | $-0.31 | $-0.55 | $-0.67 | $-0.43 | $-0.17 | $-0.15 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality